Trial Profile
Phase I Study of CSL360 in Patients With Relapsed, Refractory or High-Risk Acute Myeloid Leukemia.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 13 Apr 2016
Price :
$35
*
At a glance
- Drugs CSL 360 (Primary)
- Indications Acute myeloid leukaemia
- Focus Adverse reactions; Pharmacokinetics
- Sponsors CSL
- 22 Sep 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 30 Jun 2009 Actual patient number (40) added as reported by ClinicalTrials.gov.
- 30 Jun 2009 Planned end date changed from 1 Jun 2009 to 1 Sep 2009 as reported by ClinicalTrials.gov.